The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
HIV Drugs-Global Market Insights and Sales Trends 2025
Synopsis
HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population.
The global HIV Drugs market size is expected to reach US$ 26950 million by 2029, growing at a CAGR of 2.0% from 2023 to 2029. The market is mainly driven by the significant applications of HIV Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others, are propelling HIV Drugs market. Multi-Class Combination Products, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Nucleoside Reverse Transcriptase Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for HIV Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global HIV Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global HIV Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, HIV Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of HIV Drugs covered in this report include Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck, etc.
The global HIV Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Global HIV Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global HIV Drugs market, Segment by Type:
Multi-Class Combination Products
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Entry Inhibitors - CCR5 Co-Receptor Antagonist
HIV Integrase Strand Transfer Inhibitors
Global HIV Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of HIV Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population.
The global HIV Drugs market size is expected to reach US$ 26950 million by 2029, growing at a CAGR of 2.0% from 2023 to 2029. The market is mainly driven by the significant applications of HIV Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others, are propelling HIV Drugs market. Multi-Class Combination Products, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Nucleoside Reverse Transcriptase Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for HIV Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global HIV Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global HIV Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, HIV Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of HIV Drugs covered in this report include Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck, etc.
The global HIV Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Global HIV Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global HIV Drugs market, Segment by Type:
Multi-Class Combination Products
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Entry Inhibitors - CCR5 Co-Receptor Antagonist
HIV Integrase Strand Transfer Inhibitors
Global HIV Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of HIV Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 HIV Drugs Market Overview
1.1 HIV Drugs Product Overview
1.2 HIV Drugs Market Segment by Type
1.2.1 Multi-Class Combination Products
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Protease Inhibitors
1.2.5 Fusion Inhibitors
1.2.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
1.2.7 HIV Integrase Strand Transfer Inhibitors
1.3 Global HIV Drugs Market Size by Type
1.3.1 Global HIV Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global HIV Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global HIV Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America HIV Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe HIV Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific HIV Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America HIV Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa HIV Drugs Sales Breakdown by Type (2018-2023)
2 Global HIV Drugs Market Competition by Company
2.1 Global Top Players by HIV Drugs Sales (2018-2023)
2.2 Global Top Players by HIV Drugs Revenue (2018-2023)
2.3 Global Top Players by HIV Drugs Price (2018-2023)
2.4 Global Top Manufacturers HIV Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 HIV Drugs Market Competitive Situation and Trends
2.5.1 HIV Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by HIV Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in HIV Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into HIV Drugs Market
2.8 Key Manufacturers HIV Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 HIV Drugs Status and Outlook by Region
3.1 Global HIV Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global HIV Drugs Historic Market Size by Region
3.2.1 Global HIV Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global HIV Drugs Sales in Value by Region (2018-2023)
3.2.3 Global HIV Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global HIV Drugs Forecasted Market Size by Region
3.3.1 Global HIV Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global HIV Drugs Sales in Value by Region (2024-2029)
3.3.3 Global HIV Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global HIV Drugs by Application
4.1 HIV Drugs Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.1.4 Others
4.2 Global HIV Drugs Market Size by Application
4.2.1 Global HIV Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global HIV Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global HIV Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America HIV Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe HIV Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific HIV Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America HIV Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa HIV Drugs Sales Breakdown by Application (2018-2023)
5 North America HIV Drugs by Country
5.1 North America HIV Drugs Historic Market Size by Country
5.1.1 North America HIV Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America HIV Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America HIV Drugs Sales in Value by Country (2018-2023)
5.2 North America HIV Drugs Forecasted Market Size by Country
5.2.1 North America HIV Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America HIV Drugs Sales in Value by Country (2024-2029)
6 Europe HIV Drugs by Country
6.1 Europe HIV Drugs Historic Market Size by Country
6.1.1 Europe HIV Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe HIV Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe HIV Drugs Sales in Value by Country (2018-2023)
6.2 Europe HIV Drugs Forecasted Market Size by Country
6.2.1 Europe HIV Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe HIV Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific HIV Drugs by Region
7.1 Asia-Pacific HIV Drugs Historic Market Size by Region
7.1.1 Asia-Pacific HIV Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific HIV Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific HIV Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific HIV Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific HIV Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific HIV Drugs Sales in Value by Region (2024-2029)
8 Latin America HIV Drugs by Country
8.1 Latin America HIV Drugs Historic Market Size by Country
8.1.1 Latin America HIV Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America HIV Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America HIV Drugs Sales in Value by Country (2018-2023)
8.2 Latin America HIV Drugs Forecasted Market Size by Country
8.2.1 Latin America HIV Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America HIV Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa HIV Drugs by Country
9.1 Middle East and Africa HIV Drugs Historic Market Size by Country
9.1.1 Middle East and Africa HIV Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa HIV Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa HIV Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa HIV Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa HIV Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa HIV Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bristol-Myers Squibb
10.1.1 Bristol-Myers Squibb Company Information
10.1.2 Bristol-Myers Squibb Introduction and Business Overview
10.1.3 Bristol-Myers Squibb HIV Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bristol-Myers Squibb HIV Drugs Products Offered
10.1.5 Bristol-Myers Squibb Recent Development
10.2 Gilead Sciences
10.2.1 Gilead Sciences Company Information
10.2.2 Gilead Sciences Introduction and Business Overview
10.2.3 Gilead Sciences HIV Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Gilead Sciences HIV Drugs Products Offered
10.2.5 Gilead Sciences Recent Development
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Company Information
10.3.2 GlaxoSmithKline Introduction and Business Overview
10.3.3 GlaxoSmithKline HIV Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GlaxoSmithKline HIV Drugs Products Offered
10.3.5 GlaxoSmithKline Recent Development
10.4 Johnson & Johnson
10.4.1 Johnson & Johnson Company Information
10.4.2 Johnson & Johnson Introduction and Business Overview
10.4.3 Johnson & Johnson HIV Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Johnson & Johnson HIV Drugs Products Offered
10.4.5 Johnson & Johnson Recent Development
10.5 Merck
10.5.1 Merck Company Information
10.5.2 Merck Introduction and Business Overview
10.5.3 Merck HIV Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Merck HIV Drugs Products Offered
10.5.5 Merck Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 HIV Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 HIV Drugs Industrial Chain Analysis
11.4 HIV Drugs Market Dynamics
11.4.1 HIV Drugs Industry Trends
11.4.2 HIV Drugs Market Drivers
11.4.3 HIV Drugs Market Challenges
11.4.4 HIV Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 HIV Drugs Distributors
12.3 HIV Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
